Drug Profile
Ribuvaptan
Alternative Names: BAY-86-8050Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Bayer HealthCare Pharmaceuticals
- Class Acetamides; Carbamates; Chlorophenols; Fluorocarbons; Heart failure therapies; Small molecules; Triazoles
- Mechanism of Action Vasopressin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for phase-I development in Heart-failure in Germany
- 02 Sep 2016 Ribuvaptan is still in phase I development in Germany
- 16 Jul 2016 No recent reports of development identified for phase-I development in Heart-failure in Germany